Absorption, Distribution and Excretion
Bioavailability studies of aminosalicylic acid and its salts were conducted in 12 subjects. Colorimetric assays showed peak plasma concentrations of the sodium, potassium, calcium, and para-aminosalicylic acid salts at 0.5, 0.75, 1.5, and 3 hours, respectively. Urinary excretion data indicated that absorption was essentially complete, although absorption rates varied. Aminosalicylic acid is readily absorbed from the gastrointestinal tract. Following a single oral dose of 4 grams of free acid, plasma concentrations reached approximately 75 μg/mL within 1.5 to 2 hours. Sodium salts were absorbed more rapidly. The drug appears to be distributed throughout the body fluids, reaching higher concentrations in pleural fluid and caseous tissue. However, lower concentrations were observed in cerebrospinal fluid, likely due to active efflux. Over 80% of the drug was excreted in the urine; of this, over 50% was excreted as acetylated compounds. The remainder consisted primarily of free acid. For more complete data on the absorption, distribution, and excretion of para-aminosalicylic acid (8 metabolites), please visit the HSDB record page.

---

Metabolism/Metabolites
Hepatic metabolism.
Acetylation is a major pathway for the inactivation of many drugs, such as para-aminosalicylic acid. The enzyme that catalyzes these reactions, acetyl-CoA:N-acetyltransferase (EC 2.3.1.5), is located in the hepatocyte lysate.
After oral administration, para-aminosalicylic acid is rapidly absorbed and excreted in the urine as unaltered para-aminosalicylic acid and acetyl. Glucuronide, glycyl, and glutamyl conjugates.
In humans, it produces 5-amino-2-carboxyphenyl-β-D-glucuronide. In Pseudomonas, it produces 4-aminocatechol. In humans, it produces 4-aminosalicylglutamine and 4-aminosalicylglycine. /Table/
Blood was collected from tuberculosis patients before, during, and after treatment with five different drug combinations: isoniazid, thiazolidinedone, para-aminosalicylic acid, and streptomycin, for culture. Methods for detecting DNA damage included chromosomal aberrations and sister chromatid exchange (SCE). A total of 179 subjects were analyzed. These drugs showed synergistic, additive, and antagonistic effects when used in combination, but none were found to cause chromosome breakage when used alone. Four drug combinations—isoniazid with thiazolidinedone, isoniazid with para-aminosalicylic acid, isoniazid with thiazolidinedone and streptomycin, and isoniazid with para-aminosalicylic acid and streptomycin—significantly increased the incidence of chromosomal aberrations, while isoniazid with streptomycin did not induce chromosomal aberrations. In fact, streptomycin appeared to reduce the incidence of chromosomal aberrations. Only two patients showed an increased incidence of sister chromatid exchange (SCE): one treated with isoniazid with thiazolidinedone and the other treated with isoniazid with para-aminosalicylic acid. The incidence of chromosomal aberrations decreased after drug discontinuation; although slightly higher than the control group, the difference was not statistically significant. Recovery from chromosomal aberrations may be due to the clearance of damaged cells or DNA repair in lymphocytes. Although drug-induced abnormalities do not persist after discontinuation, caution should still be exercised when using this combination of chromosomal-damaging drugs, as the possibility of chromosomal damage occurring during germ cell meiosis during treatment cannot be ruled out, and such damage may be inherited by the next generation. For more complete metabolite/metabolite data on para-aminosalicylic acid (9 metabolites), please visit the HSDB record page. The half-life of this drug is approximately 1 hour, and plasma concentrations are negligible within 4 to 5 hours after a single dose.

Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation
Limited information suggests that low concentrations of aminosalicylic acid in breast milk are not expected to cause any adverse effects on breastfed infants, especially those older than 2 months. If this medication is used during lactation, exclusively breastfed infants should be monitored for rare occurrences such as jaundice, gastrointestinal disturbances, hypokalemia, thrombocytopenia, hemolysis, and hypokalemia.
◉ Effects on Breastfed Infants
Aminosalicylic acid was used as part of a multidrug regimen to treat two pregnant women with multidrug-resistant tuberculosis throughout pregnancy and postpartum. Both of their infants were breastfed (the extent and duration of breastfeeding were not specified). Both children were developmentally normal at 1.8 and 4.6 years of age, respectively. One child showed mild language delay at 1.8 years, while the other experienced growth retardation, possibly due to tuberculosis infection after birth.
◉ Effects on lactation and breast milk
As of the revision date, no relevant published information was found.

---

Protein binding
50-60%

---

Interactions
...para-aminosalicylic acid.../Inhibition of chloramphenicol metabolism/
Pentobarbital/SRP: Central nervous system depression/Enhanced in mice after pretreatment with para-aminosalicylic acid. INCR/SRP: Central nervous system depression/Appears to be due to the release of pentobarbital from serum protein binding, leading to increased brain concentrations...
Additive and synergistic effects with streptomycin and isoniazid.
Probenecid reduces renal excretion of this drug.
For more (complete) data on interactions of para-aminosalicylic acid (19 in total), please visit the HSDB record page.

4-Aminosalicylic acid is an aminobenzoic acid formed by substituting an amino group at the 4-position of salicylic acid. It is an anti-tuberculosis drug. It belongs to the aminobenzoic acid class of compounds and is also a phenolic compound. Its function is related to that of salicylic acid. It is the conjugate acid of 4-aminosalicylic acid (1-). It is an anti-tuberculosis drug, often used in combination with isoniazid. The sodium salt of this drug is better tolerated than the free acid. Aminosalicylic acid is a para-aminobenzoic acid (PABA) analog with anti-tuberculosis activity. Aminosalicylic acid inhibits the growth and reproduction of Mycobacterium tuberculosis by competing with para-aminobenzoic acid (PABA) for folic acid synthase, ultimately leading to cell death and exerting its antibacterial effect. Sodium aminosalicylate is the sodium salt form of aminosalicylic acid and is a para-aminobenzoic acid (PABA) analog with anti-tuberculosis activity. Sodium aminosalicylate exerts its antibacterial effect by competing with para-aminobenzoic acid (PABA) for folate synthase, thereby inhibiting the growth and reproduction of Mycobacterium tuberculosis, ultimately leading to cell death. Sodium aminosalicylate is an anti-tuberculosis drug, often used in combination with isoniazid. The sodium salt of this drug is better tolerated than the free acid. Drug Indications For the treatment of tuberculosis. When an effective treatment regimen cannot be established due to drug resistance or tolerance (see Section 4.4), Granupas is indicated for combination therapy of multidrug-resistant tuberculosis in adults and children 28 days and older. Official guidelines for the rational use of antimicrobial drugs should be consulted. Mechanism of Action The antibacterial effect of aminosalicylate against Mycobacterium tuberculosis is mainly achieved through two mechanisms. First, aminosalicylate inhibits folate synthesis (without synergistic effect with antifolate compounds). The binding of para-aminobenzoic acid to pterin synthase is the first step in folate synthesis. Aminosalicylic acid has a higher affinity for pterin synthase than para-aminobenzoic acid, effectively inhibiting folic acid synthesis. Because bacteria cannot utilize exogenous folic acid, cell growth and reproduction slow down. Secondly, aminosalicylic acid may inhibit the synthesis of mycotoxin, a cell wall component, thereby reducing iron absorption by Mycobacterium tuberculosis. The antibacterial activity of aminosalicylic acid is highly specific, affecting microorganisms other than Mycobacterium tuberculosis. Most non-tuberculous mycobacteria are not inhibited by this drug. Aminosalicylic acid is a structural analog of para-aminobenzoic acid, and its mechanism of action is very similar to that of sulfonamides. Since sulfonamides are ineffective against Mycobacterium tuberculosis, and aminosalicylic acid is also ineffective against bacteria sensitive to sulfonamides, the enzymes responsible for folic acid biosynthesis in various microorganisms may have a strong ability to distinguish between various analogs and true metabolites.

---

Therapeutic Uses
Anti-tuberculosis drug
Experimental Use: Lipid-lowering drug. 6 grams, taken for 4 weeks. Results showed that it can reduce elevated serum triglyceride and cholesterol levels. When used alone, it can sometimes successfully control tuberculosis…but resistance can develop, and toxicity limits the dosage. Therefore, para-aminosalicylic acid is almost always used in combination with one or two other anti-tuberculosis drugs. …para-aminosalicylic acid can enhance the efficacy of other drugs and delay the onset of resistance. Aminosalicylic acid…has a potent lipid-lowering effect, reducing cholesterol and triglyceride levels. However, it is poorly tolerated due to gastrointestinal reactions. For more complete data on the therapeutic uses of para-aminosalicylic acid (15 in total), please visit the HSDB record page.

---

Drug Warnings
Under no circumstances should the solution be used if its color is darker than freshly prepared solution. …Calcium, potassium, and sodium salt solutions should be prepared within 24 hours of administration.
For certain disorders that appear to be ethnically specific (such as glucose-6-phosphate dehydrogenase deficiency in erythrocytes), different drugs can cause hemolysis. Among the most notable are nitrofurantoin, aminosalicylic acid…
In patients with impaired renal function or other disorders affecting plasma concentration control, this drug can cause hypercalcemia. It can also cause urinary tract stones. /CA SALT/
The most common adverse reactions to aminosalicylic acid or its salts are gastrointestinal disturbances, including nausea, vomiting, abdominal pain, diarrhea, and anorexia. Rarely, aminosalicylic acid causes peptic ulcers and gastrointestinal bleeding. Some patients can alleviate gastrointestinal adverse reactions by taking aminosalicylic acid with food; however, symptoms may be severe enough to require discontinuation of the drug. Occasionally, patients taking aminosalicylic acid or its salts may also experience malabsorption of vitamin B12, folic acid, iron, and lipids, possibly due to increased intestinal motility. The manufacturer notes that maintenance therapy with vitamin B12 should be considered for patients taking aminosalicylic acid for more than one month. For more complete data on p-aminosalicylic acid (12 in total), please visit the HSDB records page.

---

Pharmacodynamics
Aminosalicylic acid is an antimycobacterial drug, often used in combination with other antituberculosis drugs (most commonly isoniazid) to treat various types of active tuberculosis caused by susceptible strains of Mycobacterium tuberculosis. Two key considerations in the clinical pharmacology of aminosalicylic acid are: the rapid production of toxic, inactive metabolites under acidic conditions, and the serum half-life of the free drug of only 1 hour. Aminosalicylic acid has an inhibitory effect on Mycobacterium tuberculosis (inhibiting bacterial growth without killing the bacteria). It also inhibits the development of bacterial resistance to streptomycin and isoniazid.

C7H7NO3

153.1354

153.042

65-49-6

Sodium 4-aminosalicylate dihydrate;6018-19-5;4-Aminosalicylic acid hemicalcium;133-15-3

4649

MINUTE CRYSTALS FROM ALC
WHITE, OR NEARLY WHITE, BULKY POWDER
NEEDLES, PLATES FROM ALC-ETHER
A reddish-brown crystalline powder is obtained on recrystallization from ethanol-ether.

1.5±0.1 g/cm3

380.8±32.0 °C at 760 mmHg

135-145 °C(lit.)

184.1±25.1 °C

0.0±0.9 mmHg at 25°C

1.691

1.14

83.55

3

4

1

11

160

0

O([H])C1C([H])=C(C([H])=C([H])C=1C(=O)O[H])N([H])[H]

WUBBRNOQWQTFEX-UHFFFAOYSA-N

InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)

4-amino-2-hydroxybenzoic acid

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ~100 mg/mL (~653.00 mM)

配方 1 中的溶解度: ≥ 2.5 mg/mL (16.32 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

---

配方 2 中的溶解度: ≥ 2.5 mg/mL (16.32 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。

---

View More

配方 3 中的溶解度: ≥ 2.5 mg/mL (16.32 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。